The NCI Division of Cancer Prevention funds new research in cancer prevention, detection, screening, interception, and symptom management. We also fund programs to train people for careers in research. Explore current open funding opportunities here and streamline your search by using keyword or type of funding.
Information about the funding opportunity announcements that align with the efforts of the Cancer MoonshotSM can be found here: https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding .
Notice of Funding Opportunities
Title Announcement Number
Activity Code
Clinical Trials Status
Sort descending
Expiration Date Program Official
HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment RFA-NS-22-034 (R01 Clinical Trial Not Allowed)
R01
Clinical Trial Not Allowed
12/07/2024
Rachel Altshuler, Ph.D.
Discovery and Development of Natural Products for Cancer Interception and Prevention RFA-CA-23-028 (UG3/UH3 Clinical Trial Not Allowed)
UH3, UG3
Clinical Trial Not Allowed
06/14/2025
Altaf Mohammed, Ph.D.
Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer PAR-22-061 (R01 Clinical Trial Not Allowed)
R01
Clinical Trial Not Allowed
01/08/2025
Young Kim, Ph.D.
Basic Research in Cancer Health Disparities PAR-21-323 (R21 Clinical Trial Not Allowed)
R21
Clinical Trial Not Allowed
09/08/2024
Asad Umar, D.V.M., Ph.D.
Basic Research in Cancer Health Disparities PAR-21-324 (R03 Clinical Trial Not Allowed)
R03
Clinical Trial Not Allowed
09/08/2024
Asad Umar, D.V.M., Ph.D.
Basic Research in Cancer Health Disparities PAR-21-322 (R01 Clinical Trial Not Allowed)
R01
Clinical Trial Not Allowed
09/08/2024
Asad Umar, D.V.M., Ph.D.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics PAR-23-279 (R01 Clinical Trial Optional)
R01
Clinical Trial Optional
01/08/2027
Edward Sauter, M.D., Ph.D.
Pancreatic Cancer Detection Consortium: Research Units PAR-21-334 (U01 Clinical Trial Optional)
U01
Clinical Trial Optional
06/12/2024
Matthew Young, Ph.D.
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies PAR-21-329 (R01 Clinical Trial Optional)
R01
Clinical Trial Optional
11/06/2024
Rachel Altshuler, Ph.D.
Biology of Bladder Cancer PAR-22-218 (R01 Clinical Trial Optional)
R01
Clinical Trial Optional
09/08/2025
